Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. (Q45126932)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Junya Zhu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Dhruv B Sharma

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Bruce E Johnson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Jane C Weeks

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Deborah Schrag

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

5 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

2048-2060

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Development of a comorbidity index using physician claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

The central role of the propensity score in observational studies for causal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Estimating Causal Effects from Large Data Sets Using Propensity Scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Marginal structural models and causal inference in epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

A novel classification of lung cancer into molecular subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

Staging strategies for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

7 January 2021

Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

7 January 2021

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

7 January 2021

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

7 January 2021

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

7 January 2021

Estimating treatment effects using observational data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

7 January 2021

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

7 January 2021

Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

7 January 2021

Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28022

7 January 2021

Identifiers

DOI

10.1002/CNCR.28022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23564469%20AND%20SRC:MED&resulttype=core&format=json